Skip to main content
Caplight Logo









Oak Hill Bio

Oak Hill Bio

Private
AltrinchamHealthcare & Life Scienceshttps://oakhillbio.com/

Last Round

Series A

Jun 1, 2026

Total Funding Raised

$32.5M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Oak Hill Bio is a biotechnology company that acquires and develops deprioritized late-stage rare disease drugs.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

rare disease therapyorphan drugsdrug asset acquisitionclinical-stage biotechpharma spinoutAngelman syndromeantisense oligonucleotidelate-stage developmentASO therapyneurodevelopmental disordersvirtual biotechpharma licensingrare autoimmune diseasesprematurity complicationsrecombinant proteinsmall molecule therapy

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Oak Hill Bio Comparables

Compare Oak Hill Bio with similar companies based on industry and business-model similarity.

Oak Hill Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Ultragenyx Pharmaceutical Inc.
80%
CourageAS Biotherapeutics
77%
MavriX Bio
74%

Oak Hill Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AJun 1, 2026
SeedFeb 1, 2022

Key People

Founding team and executive leadership

Sharon Morriss

Chief Operating Officer

Executive Team

Oak Hill Bio Investors

Notable investors and investment history

Oak Hill Bio investors
InvestorRounds
Janus Henderson GroupSeries A
Balyasny Asset Management L.P.Series A
venBioSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 24, 2026

    Monthly visitors increased 57% MoM.

  • Jun 1, 2026

    $33M round led by Balyasny Asset Management, Janus Henderson, and venBio.

Oak Hill Bio Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Oak Hill Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Oak Hill Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersAltrincham
Employee Range29
Year Founded2022
Last FundingJun 1, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?